Multiple endocrine neoplasia [MEN] syndromes
ICD-10 E31.2 is a billable code used to indicate a diagnosis of multiple endocrine neoplasia [men] syndromes.
Multiple endocrine neoplasia (MEN) syndromes are a group of inherited disorders characterized by the development of tumors in multiple endocrine glands. The most common types are MEN type 1 (Wermer's syndrome), MEN type 2A (Sipple syndrome), and MEN type 2B. These syndromes can lead to hyperplasia or neoplasia of the parathyroid glands, pancreas, and pituitary gland in MEN type 1, and medullary thyroid carcinoma, pheochromocytoma, and primary hyperparathyroidism in MEN type 2. Patients may present with symptoms related to hormonal imbalances, such as hypercalcemia, hypoglycemia, or Cushing's syndrome. The syndromes can also affect growth and development, particularly during puberty, leading to growth abnormalities. Polyglandular dysfunction is common, as multiple glands may be involved simultaneously, complicating diagnosis and management. Thymus disorders may also arise, particularly in MEN type 2B, where patients can develop mucosal neuromas and other neuroendocrine tumors. Early diagnosis and management are crucial to prevent complications and improve patient outcomes.
Thorough documentation of hormonal levels, imaging studies, and genetic testing results.
Patients presenting with hypercalcemia, hypoglycemia, or thyroid nodules.
Endocrinologists must ensure all affected glands are documented and monitored.
Detailed family history and genetic testing results must be documented.
Patients with a family history of endocrine tumors or syndromes.
Genetic counselors should provide clear documentation of risk assessment and testing outcomes.
Used to evaluate patients suspected of having insulinoma in MEN type 1.
Document the reason for the test and any relevant clinical findings.
Endocrinologists should ensure that the test results are correlated with clinical symptoms.
Common symptoms include hormonal imbalances leading to conditions such as hypercalcemia, hypoglycemia, and thyroid dysfunction. Patients may also experience growth abnormalities and other endocrine-related issues.
